Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.
-
Upload
bryce-allison -
Category
Documents
-
view
213 -
download
0
Transcript of Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.
![Page 1: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/1.jpg)
Blood Components Therapy Brian Poirier, M.D.
University of California, Davis Medical Center
1
![Page 2: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/2.jpg)
Topics
• Whole Blood
• Packed Red Blood Cells
• Plasma
• Platelets
• Special Transfusions/Modifications
2
![Page 3: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/3.jpg)
Modern Hemotherapy
• Administer that component of blood that the patient needs to prevent morbidity or mortality.
• The need may be due to lack of production, increased destruction or blood loss.
![Page 4: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/4.jpg)
Whole Blood Donation
4
![Page 5: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/5.jpg)
5
![Page 6: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/6.jpg)
Transfusion criteria for whole blood (Hct ~ 40% if
available)
Overt bleeding with clinical signs of hypovolemia
Exchange transfusion of a neonate (if RBCs reconstituted with FFP not available)
6
![Page 7: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/7.jpg)
7
Bristol, England, 1941
![Page 8: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/8.jpg)
Packed Red Blood Cells
8
![Page 9: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/9.jpg)
Transfuse red blood cells
• …to increase oxygen-carrying capacity in anemic patients
Do NOT transfuse red blood cells• For volume expansion• In place of a hematinic• To enhance wound healing• To improve general “well-being”
9
![Page 10: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/10.jpg)
RBC concentrates to raise Hgb level of average-size adult 1g/dL
Anticoag/Anticoag/preservativepreservative
HctHct Flow rateFlow rate DatingDating
CPDA-1CPDA-1 70-80%70-80% SlowSlow 35 days35 days
AS-5 (Optisol -AS-5 (Optisol -mannitol)mannitol)
45-59%45-59% RapidRapid 42 days42 days
AS-3 (Nutricel AS-3 (Nutricel -no mannitol)-no mannitol)
45-59%45-59% RapidRapid 42 days42 days
10
![Page 11: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/11.jpg)
RBC transfusion trigger: 7 vs. 9.5 or 10 g/dL
• 7 g/dL is as effective as 10 g/dL in adults*• 9.5 g/dL or 10 g/dL in PICU patients without
cardiovascular disease (similar morbidity and mortality)**
*Hebert PC et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409-17.
**Lacroix J et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007;365:1609-19.
11
![Page 12: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/12.jpg)
12
![Page 13: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/13.jpg)
Properties of Stored RBC’s
• Supernatant– Citrate– Potassium – free hemoglobin– pH low
• RBC– 2,3 DPG low– spherocytic change
![Page 14: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/14.jpg)
UCDMC Massive Transfusion Guideline (MTG)
Pack
6 units of pRBC
3 FFP Jumbo (or 6 regular)*
1 Plateletpheresis
*Kept thawed at 4°C for up to 5 days
14
![Page 15: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/15.jpg)
Washed Red Cells
• All Plasma and 85% of White Blood Cells are removed by washing.
15
![Page 16: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/16.jpg)
Indications for Washed Red Cells
• Urticarial transfusion reaction to several consecutive red cells transfusions.
• Anaphylactoid reaction to packed red cell transfusion (suspect IgA antibodies in an IgA deficient patient).
![Page 17: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/17.jpg)
Frozen, Thawed Deglyceralized
Red Cells• White cells and plasma are removed from
the product
17
![Page 18: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/18.jpg)
Indication for Frozen, Thawed Deglyceralized Red Cells
• Predeposition of autologous blood for elective surgery to occur >42 days after donation.
• Patient with rare or multiple antibodies that need antigenically rare blood from the local blood bank or the “rare donor file”.
• Patients with HLA antibodies where febrile reaction occurred with transfusion of washed red cells.
• History of anaphylaxis to packed red cells or washed red cells.
![Page 19: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/19.jpg)
Irradiated Blood Products• Recommended dose is between 1,500 and
5,000 cGy.• 3,000 rads destroy the spindle apparatus of
the lymphocytes so that they cannot divide. No functional impairments develop in the cells including phagocytosis by granulocytes.
• Leukemic patients, all lymphoma patients, immature infants, children with neuroblastoma receive irradiated products
![Page 20: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/20.jpg)
Indications for Irradiated Blood Products
20
![Page 21: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/21.jpg)
Autologous Blood• Encourage physicians to use this
product.
• The patient cannot develop diseases from it.
• If multiple units will be needed the patient will be placed on iron therapy.
• Criteria for transfusion remain the same.
![Page 22: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/22.jpg)
Fresh Frozen Plasma
22
![Page 23: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/23.jpg)
Male Donors
23
![Page 24: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/24.jpg)
Plasma
• Contains all the coagulation factors, albumin and fibrinogen.
• FFP (and FP24): Stored at -18°C for up to 1 year.
• Once thawed, must be used within 24 hours, or may be stored at 1-6°C for 5 days (as thawed plasma).
24
![Page 25: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/25.jpg)
Plasma: usual dose to increase clotting factor levels is 15-20
mL/kg body weight
ComponentComponent VolumeVolume
FFP (single donor)FFP (single donor) 180-250 mL180-250 mL
FP24FP24 180-250 mL180-250 mL
Jumbo FFP (single Jumbo FFP (single donor)donor)
400 mL400 mL
25
![Page 26: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/26.jpg)
Indications for Plasma
• Prolonged PT and/or PTT ( 1.5x ULN or INR >2) or coagulation factor assay 25% with active bleeding or impending surgery
• Bleeding with coagulopathy and specific concentrate unavailable
• Plasma exchange for TTP/HUS• Emergency reversal of Coumadin (Warfarin)
effect
26
(Adapted from NIH Consensus conference)
![Page 27: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/27.jpg)
Plasma Transfusion
Do NOT transfuse plasma
• For volume expansion
• As a nutritional supplement
• Prophylactically following cardiopulmonary bypass
27
![Page 28: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/28.jpg)
Plasma for TTP
ADAMTS13 is present in similar amounts in FFP, Cryo-poor plasma, and Plasma 24h and storage at 1-6°C for up to 5 days does not significantly diminish its activity, e.g., for TTP.
Scott EA et al. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion 2007;47:120-5.
28
![Page 29: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/29.jpg)
Properties of Stored Plasma
• Citrate Anticoagulant
• Coagulation Factors – Degradation of V and VII with prolonged
storage (4°C), 10 & 7 days respectively
![Page 30: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/30.jpg)
Cryoprecipitate
30
![Page 31: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/31.jpg)
Cryoprecipitate unit (bag)
Volume: 10-25 mLIncreased levels of:- Factor VIII ( 100 U)- Fibrinogen (200-300 mg)- Von Willebrand’s factor- Factor XIII- ADAMTS13
Usual dose – 10 bags/adult
N.B. – once thawed, keep at room temp
31
![Page 32: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/32.jpg)
Indications for Cryoprecipitate
• No longer recommended for mild hemophilia A.• It is better to use heat treated factor VIII since HIV is
destroyed by heat.
– D.I.C– Von Willebrand’s disease– Massive intra-abdominal clotting in liver
lacerations– Fibrin glue (cryoprecipitate is mixed with
thrombin and applied directly to blood vessels)
![Page 33: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/33.jpg)
33
![Page 34: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/34.jpg)
Platelets
34
![Page 35: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/35.jpg)
PLATELET AGITATION AT ROOM TEMPARATURE
![Page 36: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/36.jpg)
Platelets
• A platelet pack contains 5.5 x 1010 platelets and can raise the platelet count 10,000 mm3 maximally.
• A plateletpheresis contains 3 x 1011 platelets and can raise the platelet count 30,000 mm3.
36
![Page 37: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/37.jpg)
Properties of Stored Platelets
• Citrate
• Cytokines/Vasoactive Substances
![Page 38: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/38.jpg)
Indications for Platelets
• Prevention or arrest of bleeding in thrombocytopenic patients
• Maintain a platelet count 10,000 – 20,000 mm3 in medical cases
• Maintain a platelet count 50,000 – 100,000 mm3 in surgical cases
• GI bleeder who has taken aspirin
![Page 39: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/39.jpg)
Indications for Platelets
• Non-bleeding patient with count of <10,000/mm3 or 1x109/L
• Platelet count < 50,000/mm3 or 5x109/L and - Bleeding due to thrombocytopenia and/or - Surgical/invasive procedure imminent
• Documented abnormal platelet function with bleeding or surgical/invasive procedure imminent
39
![Page 40: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/40.jpg)
Platelet transfusion
Do NOT transfuse platelets• To patients with immune
thrombocytopenic purpura (unless there is life-threatening bleeding)
• Prophylactically following cardiopulmonary bypass
40
![Page 41: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/41.jpg)
ABO Compatible Blood Components
Blood Compatible Compatible
Type RBCs FFPs A A, O A, AB
B B, O B, AB
AB AB, A, B, O AB
O O A, B, AB, O
4104/18/23
![Page 42: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/42.jpg)
Editorial: Platelet ABO matters. RM Kaufman Transfusion
2009;49:5-7.PLT recovery is not the only problem
with ABO-incompatible PLTs• In ABO minor-incompatible PLTs, anti-A/B
is passively transfused and, rarely, causes acute hemolysis
• PLT ABO incompatibility – major or minor – should be avoided whenever possible
42
![Page 43: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/43.jpg)
ABO Compatibility Study
Julmy F, Amman RA, Taleghani BM, et al. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs. Transfusion 2009;49: 21-33.
43
![Page 44: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/44.jpg)
Julmy F et al. (cont.)
• ABO major-mismatched PLTs, (e.g., A1 to O or B), result in lower 1 hr post counts (21% vs. 32%)
• ABO major-mismatched PLTs more often unsuccessful
• Platelets expressing A1 on their surface are cleared in O or B recipients
• A2 PLTs, expressing no detectable A, were as successful as ABO identical PLTs
44
![Page 45: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/45.jpg)
Julmy et al. (cont.)
Conclusions
• In children, ABO major-mismatched PLT transfusions result in inferior efficacy, except for A2 PLTs
• ABO minor-mismatched PLTs showed comparable efficacy to identical PLTs
45
![Page 46: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/46.jpg)
Other Products andSpecial Considerations
46
![Page 47: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/47.jpg)
Granulocyte Transfusions
47
![Page 48: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/48.jpg)
Granulocyte Transfusions
• Severely neutropenic patients (Absolute Neutrophil count <500/mm3) with sepsis (especially if Gram negative bacteria)
- Unresponsive to 24-48 hrs. of appropriate antibiotics
- Reasonable chance of marrow recovery soon
- Progressive cellulitis
• Neonatal sepsis with transient granulocytopenia
48
![Page 49: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/49.jpg)
Leukocyte-Depleted Components: Advantages
Sensitization to wbc
Febrile reactions (and some TRALI)
Risk of cell-associated viruses, e.g., CMV (and bacteria)
Response to platelet transfusions49
![Page 50: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/50.jpg)
No benefit of leukocyte reduction for HIV-infected
patients
“Specifically, there was no difference in survival…in HIV-1 related serious events, nor…in the rate of transfusion reactions.”
50
Collier AC et al. Leukocyte-reduced red blood cell transfusions in patientswith anemia and human immunodeficiency virus infection. The ViralActivation Transfusion Study: A randomized controlled trial. JAMA 2001;285:1592-1601.
![Page 51: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/51.jpg)
CMV seronegative (cellular) components
• Intrauterine transfusions.
• Premature infants (<1200 g) born to CMV seronegative mothers.
• CMV seronegative transplant candidates receiving CMV negative tissues/organs.
• CMV seronegative pregnant women.
• CMV seronegative, HIV-infected patients.
51
![Page 52: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/52.jpg)
Alternatives to standard allogeneic transfusions
• Hemodilution
• Intraoperative autologous transfusion
• Perioperative blood salvage
• Lower transfusion trigger
• Pharmacologic therapies
• Pathogen inactivated components
• Red cell substitutes
52
![Page 53: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/53.jpg)
The ideal red cell substitute
• Delivers oxygen (and maybe enhances delivery)
• Does not transmit disease
• Does not have immunosuppresive effects
• Available in abundant supply
• Universally compatible
53
![Page 54: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/54.jpg)
Characteristics of HBOC(Hemoglobin-based Oxygen
Carriers)ProductProduct PolyHemePolyHeme HemopureHemopure HemospanHemospan
CompanyCompany NorthfieldNorthfield BiopureBiopure SangartSangart
Volume (mL)Volume (mL) 500500 250250 250 or 500250 or 500
Hb ConcHb Conc 10 g/dL10 g/dL 13 g/dL13 g/dL 4.2 g/dL4.2 g/dL
Hb Mass (g)Hb Mass (g) 5050 ~30~30 ~10 or 20~10 or 20
PP5050 (mmHg) (mmHg) 26-3226-32 3838 66
Met [Hb]Met [Hb] <8.0%<8.0% <15.0%<15.0% <0.5%<0.5%
TetramerTetramer 1.0%1.0% 3.0%3.0% 1.0%1.0%
Shelf-lifeShelf-life >1 year>1 year 3 years3 years >1 year>1 year
54
![Page 55: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/55.jpg)
Blood substitutes increase risk of death
• 16 trials of hemoglobin-based blood substitutes – 3,711 patients
• 30% increase in risk of death
• ~ 3 fold chance of heart attack
Natanson C et al. JAMA May 21, 2008
55
![Page 56: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/56.jpg)
56
![Page 57: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/57.jpg)
Scientists take step toward converting A and B Red Blood Cells to Universal O
Bacterial enzymes can remove A & B antigens at room temperature in neutral pH: B. fragilis enzyme removes B antigen E. meningosepticum enzyme targets A antigen
Liu QP et al. Bacterial glycosidases for the production of universal red blood cells. Nat Biotechnol 2007;25:1-11.
57
![Page 58: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/58.jpg)
Thank You!
58
![Page 59: Blood Components Therapy Brian Poirier, M.D. University of California, Davis Medical Center 1.](https://reader038.fdocuments.in/reader038/viewer/2022110206/56649d0a5503460f949dc701/html5/thumbnails/59.jpg)
59